GSK5764227 + carboplatin

GSK5764227 + carboplatin is a combination investigational therapy comprised of GSK5764227, a B7-H3-targeted antibody-drug conjugate, and carboplatin, a platinum-based chemotherapy agent. GSK5764227 is a fully human anti–B7-H3 monoclonal antibody conjugated via protease-cleavable linker to a topoisomerase I inhibitor payload. The ADC targets B7-H3, an immune checkpoint protein overexpressed on various solid tumors (with limited normal tissue expression), facilitating the selective delivery of cytotoxic agent to tumor cells. Carboplatin is a DNA crosslinking agent that induces apoptosis in rapidly dividing cells. This combination is being evaluated in clinical trials for advanced solid tumors, including but not limited to extensive-stage small-cell lung cancer (ES-SCLC), osteosarcoma, and sarcoma. GSK5764227 is developed by GSK with Hansoh Pharma originating the compound in China; carboplatin is a well-established generic antineoplastic agent produced by multiple manufacturers globally[1][2][3][4][5][6].

Other names

GSK’227 + carboplatin